# Boston Scientific sells BTG Specialty Pharmaceuticals to SERB for $800M

Boston Scientific announced the sale of its BTG Specialty Pharmaceuticals business to European specialty pharmaceutical group SERB for $800 million, completing the divestiture of non-device assets acquired with BTG.

- Type: Acquisition
- Announced: 2020-12-01
- Value: $800.0M
- Status: announced
- Products: specialty pharmaceuticals
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Boston Scientific](https://endata.com/companies/15966.md)
- [Boston Scientific](https://endata.com/companies/15966.md) (partner)
- [SERB](https://endata.com/companies/51572.md) (acquirer)
- [Stark International Lux](https://endata.com/companies/51683.md) (acquirer)

## Sources

- [medtechdive.com](https://www.medtechdive.com/news/zimmer-acquires-ae-medical-boston-scientific-sells-btg-pharma-assets-serb/589885/), 2020-12-01: "Boston Scientific’s sale of the BTG business to European specialty pharmaceutical group SERB for $800 million completes its divestiture of recently acquired non-device assets."
- [mddionline.com](https://www.mddionline.com/cardiovascular/medtech-in-a-minute-divestitures-and-m-a-oh-my-), 2020-12-07: "Boston Scientific is whittling down the non-device portions of its BTG acquisition with another divestiture."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.